Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.4%
    Check dated 2025-06-19T20:02:33.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:19:53.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.7%
    Check dated 2025-05-29T06:05:11.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-30T14:21:31.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The webpage has added a section with helpful links provided by Pfizer, which includes information on how to obtain contact details for a study center nearby.
    Difference
    0.3%
    Check dated 2025-04-23T12:33:49.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical study involving ARRY-382 and pembrolizumab, while retaining the study's identifier and revision number.
    Difference
    12%
    Check dated 2025-04-16T10:22:11.000Z thumbnail image

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.